Pilot pharmacologic randomized controlled trial for psychogenic nonepileptic seizures

Neurology

Volumn 75, Issue 13, 2010, Pages 1166-1173

  Lafrance, W C ^a,b   Keitner, G I ^b   Papandonatos, G D ^c   Blum, A S ^a   MacHan, J T ^b   Ryan, C E ^b   Miller, I W ^b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SERTRALINE; ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; PSYCHOGENIC NONEPILEPTIC SEIZURE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEIZURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; DOSE RESPONSE; METHODOLOGY; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; VIDEORECORDING;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SEIZURES; SERTRALINE; TREATMENT OUTCOME; VIDEO RECORDING; YOUNG ADULT;

EID: 77957948393     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f4d5a9     Document Type: Article

References (40)

1. Gowers WR. Treatment: hysteroid attacks. In: Epilepsy and Other Chronic Convulsive Diseases: Their Causes, Symptoms, and Treatment. 2nd ed. London: Churchill; 1901:299-301.
2. Shulman KI, Silver IL. Hysterical seizures as a manifestation of "depression" in old age. Can J Psychiatry 1985;30: 278-280.
3. LaFrance WC Jr, Devinsky O. The treatment of nonepi-leptic seizures: historical perspectives and future directions. Epilepsia 2004;45(suppl 2):15-21.
4. LaFrance WC Jr, Barry JJ. Update on treatments of psychological nonepileptic seizures. Epilepsy Behav 2005;7: 364-374.
5. Brooks JL, Goodfellow L, Bodde NM, Aldenkamp A, Baker GA. Nondrug treatments for psychogenic nonepi-leptic seizures: what's the evidence? Epilepsy Behav 2007; 11:367-377.
6. LaFrance WC Jr, Alper K, Babcock D, et al. Nonepileptic seizures treatment workshop summary. Epilepsy Behav 2006;8:451-461.
7. Noyes R Jr, Happel RL, Muller BA, et al. Fluvoxamine for somatoform disorders: an open trial. Gen Hosp Psychiatry 1998;20:339-344.
8. Varia I, Logue E, O'Connor C, et al. Randomized trial of sertraline in patients with unexplained chest pain of non-cardiac origin. Am Heart J 2000;140:367-372.
9. Volz HP, Moller HJ, Reimann I, Stoll KD. Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial. Eur Neuropsychopharmacol 2000;10:211-217.
10. Menza M, Lauritano M, Allen L, et al. Treatment of som-atization disorder with nefazodone: a prospective, open-label study. Ann Clin Psychiatry 2001;13:153-158.
11. Voon V, Lang AE. Antidepressant treatment outcomes of psychogenic movement disorder. J Clin Psychiatry 2005; 66:1529-1534.
12. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:85-102.
13. LaFrance WC Jr, Blum AS, Miller IW, Ryan CE, Keitner GI. Methodological issues in conducting treatment trials for psychological nonepileptic seizures. J Neuropsychiatry Clin Neurosci 2007;19:391-398.
14. Newton-Howes G, Tyrer P. Pharmacotherapy for personality disorders. Expert Opin Pharmacother 2003;4:1643-1649.
15. Bowman ES, Markand ON. Psychodynamics and psychiatric diagnoses of pseudoseizure subjects. Am J Psychiatry 1996;153:57-63.
16. Rausch JL, LaFrance C, Stahl SM. Serotonin receptor-specific mediation of antidepressant treatment effects in depressed patients. Int Rev Psychiatry 1995;7:85-98.
17. Apter A, van Praag HM, Plutchik R, Sevy S, Korn M, Brown SL. Interrelationships among anxiety, aggression, impulsivity, and mood: a serotonergically linked cluster? Psychiatry Res 1990;32:191-199.
18. LaFrance WC Jr, Syc S. Depression and symptoms affect quality of life in psychogenic nonepileptic seizures. Neurology 2009;73:366-371.
19. Fawcett J, Epstein P, Fiester SJ, Elkin I, Autry JH. Clinical Management: Imipramine/Placebo Administration Manual. NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol Bull 1987;23:309-324.
20. LaFrance WC Jr, Miller IW, Ryan CE, et al. Cognitive behavioral therapy for psychogenic nonepileptic seizures. Epilepsy Behav 2009;14:591-596.
21. Zimmerman M, Chelminski I, Posternak MA. Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included. J Nerv Ment Dis 2004;192:87-94.
22. Keitner GI, Posternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry 2003;64:1091-1093.
23. Ataoglu A, Sir A, Ozkan M. Paradoxical therapy in conversion disorder. Turk J Med Sci 1998;28:419-421.
24. Blumer D. Chapter 24. On the psychobiology of non-epileptic seizures. In: Gates JR, Rowan AJ, eds. Non-Epileptic Seizures. 2nd ed. Boston: Butterworth-Heine-mann; 2000:305-310.
25. Baker GA, Brooks JL, Goodfellow L, Bodde N, Alden-kamp A. Treatments for non-epileptic attack disorder. Co-chrane Database Syst Rev 2007;(1):CD006370.
26. Gross RA, Johnston KC. Levels of evidence: taking Neurology® to the next level. Neurology 2009;72:8-10.
27. Jackson JL, O'Malley PG, Kroenke K. Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectr 2006;11:212-222.
28. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-Second Edition (BDI-II). San Antonio: Psychological Corp.; 1996.
29. Miller IW, Bishop S, Norman WH, Maddever H. The Modified Hamilton Rating Scale for Depression: reliability and validity. Psychiatry Res 1985;14:131-142.
30. Davidson J. Davidson Trauma Scale. New York: Multi-Health Systems Inc.; 1996.
31. Bernstein EM, Putnam FW. Development, reliability, and validity of a dissociation scale. J Nerv Ment Dis 1986;174: 727-735.
32. Barratt ES, Stanford MS, Kent TA, Felthous A. Neuropsy-chological and cognitive psychophysiological substrates of impulsive aggression. Biol Psychiatry 1997;41:1045-1061.
33. Epstein NB, Baldwin LM, Bishop DS. The McMaster Family Assessment Device. J Marital Fam Ther 1983;9: 171-180.
34. Ryan CE, Epstein NB, Keitner GI, Miller IW, Bishop DS. Evaluating and Treating Families: The McMaster Approach. New York: Routledge; 2005.
35. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale-preliminary report. Psychophar-macol Bull 1973;9:13-28.
36. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33:766-771.
37. Bamford JM, Sandercock PA, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989;20:828.
38. Leon AC, Solomon DA, Mueller TI, Turvey CL, Endicott J, Keller MB. The Range of Impaired Functioning Tool (LIFE-RIFT): a brief measure of functional impairment. Psychol Med 1999;29:869-878.
39. Vitaliano PP, Russo J, Carr JE, Maiuro RD, Becker J. The Ways of Coping checklist: revision and psychometric properties. Multivariate Behav Res 1985;20:3-26
40. Vickrey BG, Perrine KR, Hays RD, et al., eds. Quality of Life in Epilepsy: QOLIE-31-Scoring Manual. Version 1.0. Santa Monica: RAND; 1993